Pages that link to "Q68163318"

The following pages link to Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial (Q68163318):

Displaying 39 items.

• Immunobiology and immunotherapy in genitourinary malignancies (Q26738668) (← links)
• Tumors of the kidney, ureter, and bladder (Q33560238) (← links)
• Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer (Q33851144) (← links)
• Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer (Q34062336) (← links)
• Medical management of patients with refractory carcinoma in situ of the bladder (Q34273634) (← links)
• Update on intravesical agents for non-muscle-invasive bladder cancer (Q34584575) (← links)
• Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review (Q34751946) (← links)
• Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies (Q34799858) (← links)
• Superficial bladder cancer: Diagnosis, surveillance and treatment (Q35223205) (← links)
• Evaluation and follow-up strategies for superficial bladder cancer. (Q35609559) (← links)
• Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma (Q36054205) (← links)
• Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. (Q36111213) (← links)
• High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder (Q36363238) (← links)
• The management of superficial transitional cell carcinoma of the bladder. (Q36418397) (← links)
• Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro (Q36718645) (← links)
• Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette-Guerin: A single center experience and analysis of prognostic factors. (Q37094285) (← links)
• Immunotherapy for urothelial carcinoma: current status and perspectives (Q37137381) (← links)
• Biologic response modifiers and urologic malignancies (Q38193573) (← links)
• Immune therapies in non-muscle invasive bladder cancer (Q38372571) (← links)
• New Strategies in Bladder Cancer: A Second Coming for Immunotherapy (Q38673585) (← links)
• Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer (Q42221034) (← links)
• Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute (Q42324419) (← links)
• Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer (Q46851166) (← links)
• Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer? (Q60049218) (← links)
• A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer (Q64065784) (← links)
• Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal? (Q64262653) (← links)
• Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response (Q67552739) (← links)
• Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder Tumors (Q68331143) (← links)
• Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer (Q70245435) (← links)
• Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer (Q72288126) (← links)
• Indications for BCG in surface tumors of the bladder (Q73234107) (← links)
• BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes (Q73269837) (← links)
• Intravesical therapy of superficial bladder cancer (Q73755473) (← links)
• Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer (Q73836223) (← links)
• Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder (Q77507915) (← links)
• Long-term maintenance bacille Calmette-Guérin therapy in high-grade superficial bladder cancer (Q77732405) (← links)
• The management of superficial bladder cancer (Q80275684) (← links)
• Intravesical BCG for bladder cancer: how much is enough? (Q81430190) (← links)
• Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancer (Q82984523) (← links)